CelLBxHealth PLC - Board changes
CelLBxHealth plc (the "Company")
Board changes
·
·
·
·
The information required in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies is detailed at the end of this announcement.
Separately Non-Executive Director,
For further information:
|
CelLBxHealth plc |
+44 (0) 1483 343434 |
|
Cavendish (NOMAD and Broker) |
+44 (0) 20 7220 0500 |
|
FTI Consulting Simon |
+44 (0) 203 727 1000 |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of
About CelLBxHealth plc
CelLBxHealth plc is a leading CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Laboratory services: Clinical trial support and assay development (3) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme.
The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified
For more information, visit https://cellbxhealth.com/.
AIM Rules Schedule 2 (g) information
The directorships and partnerships currently held by
|
Current directorships |
Previous directorships held in the past five years |
||
|
|
|
The directorships and partnerships currently held by Klaas De Boer, aged 60, and over the five years preceding the date of this announcement are as follows:
|
Current directorships |
Previous directorships held in the past five years |
|
Tsjukemar Ltd General Fusion Inc Xeros Technology Group plc SmartKem Inc Smartkem Ltd Fashion for Good BV |
Entrepreneurs Fund Management LLP Entrepreneurs Fund Management Services Ltd veriNOS Pharmaceuticals GmbH (Previously known as vasopharm GmbH) Stichting Administratiekantoor Bellevue
|
The directorships and partnerships currently held by
|
Current directorships |
Previous directorships held in the past five years |
|
|
Applied Technology Partners LLC |
The directorships and partnerships currently held by
|
Current directorships |
Previous directorships held in the past five years |
||
|
|
There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE